Title : Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells.

Pub. Date : 2014

PMID : 25477962






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this study we investigated the effects of the small molecular agent NU6140 (inhibits CDK2 and cyclin A interaction) on human embryonic stem (hES) cells and embryonal carcinoma-derived (hEC) cells via the expression of transcription factors responsible for pluripotency. 4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide ribosome binding protein 1 Homo sapiens
2 Both hES and hEC cells responded to NU6140 treatment by induced apoptosis and a decreased expression of NANOG, OCT4, and SOX2 in surviving cells. 4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide ribosome binding protein 1 Homo sapiens
3 A higher sensitivity to NU6140 application in hES than hEC cells was detected. 4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide ribosome binding protein 1 Homo sapiens
4 NU6140 treatment arrested hES and hEC cells in the G2 phase and inhibited entry into the M phase as evidenced by no significant increase in histone 3 phosphorylation. 4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide ribosome binding protein 1 Homo sapiens